» Articles » PMID: 21423609

Identification of CD4+ T Cell Epitopes in C. Burnetii Antigens Targeted by Antibody Responses

Overview
Journal PLoS One
Date 2011 Mar 23
PMID 21423609
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Coxiella burnetii is an obligate intracellular gram-negative bacterium that causes acute Q fever and chronic infections in humans. A killed, whole cell vaccine is efficacious, but vaccination can result in severe local or systemic adverse reactions. Although T cell responses are considered pivotal for vaccine derived protective immunity, the epitope targets of CD4(+) T cell responses in C. burnetii vaccination have not been elucidated. Since mapping CD4(+) epitopes in a genome with over 2,000 ORFs is resource intensive, we focused on 7 antigens that were known to be targeted by antibody responses. 117 candidate peptides were selected from these antigens based on bioinformatics predictions of binding to the murine MHC class II molecule H-2 IA(b). We screened these peptides for recognition by IFN-γ producing CD4(+) T cell in phase I C. burnetii whole cell vaccine (PI-WCV) vaccinated C57BL/6 mice and identified 8 distinct epitopes from four different proteins. The identified epitope targets account for 8% of the total vaccination induced IFN-γ producing CD4(+) T cells. Given that less than 0.4% of the antigens contained in C. burnetii were screened, this suggests that prioritizing antigens targeted by antibody responses is an efficient strategy to identify at least a subset of CD4(+) targets in large pathogens. Finally, we examined the nature of linkage between CD4(+) T cell and antibody responses in PI-WCV vaccinated mice. We found a surprisingly non-uniform pattern in the help provided by epitope specific CD4(+) T cells for antibody production, which can be specific for the epitope source antigen as well as non-specific. This suggests that a complete map of CD4(+) response targets in PI-WCV vaccinated mice will likely include antigens against which no antibody responses are made.

Citing Articles

Q Fever Vaccines: Unveiling the Historical Journey and Contemporary Innovations in Vaccine Development.

Christodoulou M, Papagiannis D Vaccines (Basel). 2025; 13(2).

PMID: 40006698 PMC: 11861857. DOI: 10.3390/vaccines13020151.


Synthetic Particulate Subunit Vaccines for the Prevention of Q Fever.

Sam G, Plain K, Chen S, Islam A, Westman M, Marsh I Adv Healthc Mater. 2024; 13(7):e2302351.

PMID: 38198823 PMC: 11468694. DOI: 10.1002/adhm.202302351.


Genome-wide epitope mapping across multiple host species reveals significant diversity in antibody responses to vaccination and infection.

Bach E, Fitzgerald S, Williams-MacDonald S, Mitchell M, Golde W, Longbottom D Front Immunol. 2023; 14:1257722.

PMID: 37954609 PMC: 10637584. DOI: 10.3389/fimmu.2023.1257722.


Engineering Protein Nanoparticles Functionalized with an Immunodominant Antigen to Generate a Q Fever Vaccine.

Ramirez A, Felgner J, Jain A, Jan S, Albin T, Badten A Bioconjug Chem. 2023; 34(9):1653-1666.

PMID: 37682243 PMC: 10515490. DOI: 10.1021/acs.bioconjchem.3c00317.


Immunisation with purified Coxiella burnetii phase I lipopolysaccharide confers partial protection in mice independently of co-administered adenovirus vectored vaccines.

Dold C, Zhu H, Silva-Reyes L, Blackwell L, Linder A, Bewley K Vaccine. 2023; 41(19):3047-3057.

PMID: 37037709 PMC: 10914673. DOI: 10.1016/j.vaccine.2023.04.012.


References
1.
Varghees S, Kiss K, Frans G, Braha O, Samuel J . Cloning and porin activity of the major outer membrane protein P1 from Coxiella burnetii. Infect Immun. 2002; 70(12):6741-50. PMC: 133000. DOI: 10.1128/IAI.70.12.6741-6750.2002. View

2.
Dellacasagrande J, Ghigo E, Raoult D, Capo C, Mege J . IFN-gamma-induced apoptosis and microbicidal activity in monocytes harboring the intracellular bacterium Coxiella burnetii require membrane TNF and homotypic cell adherence. J Immunol. 2002; 169(11):6309-15. DOI: 10.4049/jimmunol.169.11.6309. View

3.
Murphey C, Murthy A, Meier P, Guentzel M, Zhong G, Arulanandam B . The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells. Cell Immunol. 2006; 242(2):110-7. PMC: 1885537. DOI: 10.1016/j.cellimm.2006.10.002. View

4.
Richards K, Chaves F, Krafcik F, Topham D, Lazarski C, Sant A . Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutinin. J Virol. 2007; 81(14):7608-19. PMC: 1933370. DOI: 10.1128/JVI.02834-06. View

5.
Coleman S, Fischer E, Howe D, Mead D, Heinzen R . Temporal analysis of Coxiella burnetii morphological differentiation. J Bacteriol. 2004; 186(21):7344-52. PMC: 523218. DOI: 10.1128/JB.186.21.7344-7352.2004. View